BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 17006847)

  • 21. Polymorphisms in the RET proto-oncogene and the phenotypic presentation of familial medullary thyroid carcinoma.
    Magalhães PK; de Castro M; Elias LL; Soares EG; Maciel LM
    Thyroid; 2004 Oct; 14(10):848-52. PubMed ID: 15588382
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Management of multiple endocrine neoplasia syndrome type 2 families in association with rare germline mutations of the RET proto-oncogene].
    Fitze G; Saeger HD; Roesner D; Schackert HK
    Klin Padiatr; 2004; 216(5):270-6. PubMed ID: 15455293
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple endocrine neoplasia type 2 and sporadic medullary thyroid carcinoma: Turkish experience.
    Erdogan MF; Gursoy A
    Pediatr Endocrinol Rev; 2006 Aug; 3 Suppl 3():503-7. PubMed ID: 17551473
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.
    Elisei R; Romei C; Cosci B; Agate L; Bottici V; Molinaro E; Sculli M; Miccoli P; Basolo F; Grasso L; Pacini F; Pinchera A
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4725-9. PubMed ID: 17895320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Mutations of ret-proto-oncogene in thyroid medullary carcinoma].
    Frank-Raue K; Höppner W; Buhr H; Herfarth C; Ziegler R; Raue F
    Dtsch Med Wochenschr; 1997 Feb; 122(6):143-9. PubMed ID: 9081799
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutational spectrum of multiple endocrine neoplasia type 2 and sporadic medullary thyroid carcinoma in taiwan.
    Chang CF; Yang WS; Su YN; Wu IL; Chang TC
    J Formos Med Assoc; 2009 May; 108(5):402-8. PubMed ID: 19443294
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aggressive inherited and sporadic medullary thyroid carcinomas display similar oncogenic pathways.
    Ameur N; Lacroix L; Roucan S; Roux V; Broutin S; Talbot M; Dupuy C; Caillou B; Schlumberger M; Bidart JM
    Endocr Relat Cancer; 2009 Dec; 16(4):1261-72. PubMed ID: 19675075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations.
    de Groot JW; Plaza Menacho I; Schepers H; Drenth-Diephuis LJ; Osinga J; Plukker JT; Links TP; Eggen BJ; Hofstra RM
    Surgery; 2006 Jun; 139(6):806-14. PubMed ID: 16782438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical manifestations of familial medullary thyroid carcinoma.
    Kameyama K; Okinaga H; Takami H
    Biomed Pharmacother; 2004; 58(6-7):348-50. PubMed ID: 15271414
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Medullary carcinoma of the thyroid gland and the MEN 2 syndromes.
    Skinner MA; Wells SA
    Semin Pediatr Surg; 1997 Aug; 6(3):134-40. PubMed ID: 9263335
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medullary thyroid carcinoma: including MEN 2A and MEN 2B syndromes.
    Quayle FJ; Moley JF
    J Surg Oncol; 2005 Mar; 89(3):122-9. PubMed ID: 15719378
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transcriptome analysis in mouse tumors induced by Ret-MEN2/FMTC mutations reveals subtype-specific role in survival and interference with immune surveillance.
    Engelmann D; Koczan D; Ricken P; Rimpler U; Pahnke J; Li Z; Pützer BM
    Endocr Relat Cancer; 2009 Mar; 16(1):211-24. PubMed ID: 18984779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey.
    Aydoğan Bİ; Yüksel B; Tuna MM; Navdar Başaran M; Akkurt Kocaeli A; Ertörer ME; Aydın K; Güldiken S; Şimşek Y; Cihan Karaca Z; Yılmaz M; Aktürk M; Anaforoğlu İ; Kebapçı N; Duran C; Taşlıpınar A; Kulaksızoğlu M; Gürsoy A; Dağdelen S; Erdoğan MF
    J Clin Res Pediatr Endocrinol; 2016 Mar; 8(1):13-20. PubMed ID: 26758973
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
    Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
    Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hereditary Medullary Thyroid Cancer Genotype-Phenotype Correlation.
    Frank-Raue K; Raue F
    Recent Results Cancer Res; 2015; 204():139-56. PubMed ID: 26494387
    [TBL] [Abstract][Full Text] [Related]  

  • 36. C-cell hyperplasia and medullary thyroid carcinoma: clinicopathological and genetic correlations in 66 consecutive patients.
    Guyétant S; Josselin N; Savagner F; Rohmer V; Michalak S; Saint-André JP
    Mod Pathol; 2003 Aug; 16(8):756-63. PubMed ID: 12920219
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiple endocrine neoplasia type 2.
    Lodish M
    Front Horm Res; 2013; 41():16-29. PubMed ID: 23652668
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic testing in endocrinology: lessons learned from experience with multiple endocrine neoplasia type 2 (MEN2).
    Jimenez C; Gagel RF
    Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S150-7. PubMed ID: 15135800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Thyroid carcinomas and Hirschsprung's disease--10-year experience with molecular genetic testing of the RET proto-oncogene].
    Bendlová B; Dvoráková S; Václavíková E; Sýkorová V; Vlcek P; Skába R
    Vnitr Lek; 2006 Oct; 52(10):926-34. PubMed ID: 17063805
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Medullary thyroid carcinoma in Northern Ireland, 1967-1997.
    Dolan SJ; Russell CF
    Ann R Coll Surg Engl; 2000 May; 82(3):156-61. PubMed ID: 10858675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.